Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Otsuka Holdings Company ADR
(OP:
OTSKY
)
23.93
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Jul 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
23.93
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
23.93
Today's Range
23.93 - 23.93
52wk Range
16.04 - 24.74
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024
May 17, 2024
Otsuka Holdings just reported results for the first quarter of 2024.
Via
InvestorPlace
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
April 16, 2024
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo.
Via
Benzinga
Performance
YTD
+28.52%
+28.52%
1 Month
+15.72%
+15.72%
3 Month
+19.47%
+19.47%
6 Month
+23.54%
+23.54%
1 Year
+26.82%
+26.82%
More News
Read More
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
March 20, 2024
Via
Benzinga
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
August 24, 2023
Via
Benzinga
Exposures
Product Safety
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
August 23, 2023
Via
Benzinga
Exposures
Product Safety
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
August 05, 2022
Via
Benzinga
Why Are Akebia Therapeutics Shares Falling Today?
May 16, 2022
Via
Benzinga
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
March 30, 2022
Via
Benzinga
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
May 11, 2023
Via
Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
November 03, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
July 01, 2022
Via
Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
January 31, 2022
Via
Talk Markets
4 Pre-Merger SPACs to Buy That Are Poised to Soar
November 16, 2021
Via
InvestorPlace
Topics
Electric Vehicles
Exposures
Electric Vehicles
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
June 01, 2021
Via
Benzinga
Exposures
Product Safety
3 Cheap Pharmaceutical Stocks to Grab Now
May 28, 2021
Via
Talk Markets
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.